Baxter’s Chinese API Supplier Cited For “Objectionable Practices;” Remaining Heparin Vials Recalled

U.S. FDA has issued a Form 483 to Changzhou SPL, Baxter Healthcare's heparin API supplier, after inspecting the Changzhou City plant, FDA announced Feb. 28 during an update of the agency's ongoing investigation of Baxter's heparin products

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Archive

More from Scrip